Invest in the Future of Kidney Care with Assure CKD

Investors

AssureCKD is aims to reduce the ~$150 billion in annual costs (USA) associated with chronic kidney disease (CKD). By providing a lab-equivalent device at the point-of-care, we increase testing among high- risk patients and facilitate early detection and. More screening leads to more diagnoses, timely treatment, and the ability to slow or even stop CKD progression. Join us in our mission to expand CKD screening and reduce the burden of end-stage renal disease!

Let’s work together.

Interested in learning more about our company and upcoming investment opportunities? Please fill out the form and we’ll get back to you promptly.